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Objective To assess the susceptibility of the key respiratory pathogens Streptococcus pneumoniae, Haemophilus
influenzae and Moraxella catarrhalis to antimicrobial agents used to treat respiratory tract infections.
Methods Isolates were collected from five centers in Brazil during 1997–98, and susceptibility testing was
conducted at a central laboratory according to National Committee for Clinical Laboratory Standards criteria.
Results Of the 359 Streptococcus pneumoniae isolates tested, 77% were susceptible, 19% were intermediate and
4% were resistant to penicillin. The susceptibility of S. pneumoniae to other b-lactams and macrolides was
greater than 90%, but cotrimoxazole was active against only 48% of the isolates. The prevalence of susceptible
isolates was 100.0% for vancomycin and 99.7% for levofloxacin. b-Lactam, macrolide, and cotrimoxazole
activities were negatively associated with penicillin resistance. Of the 219 isolates of Haemophilus influenzae
tested, 11% produced b-lactamase and 11% were not susceptible to ampicillin. Nearly all H. influenzae isolates
were susceptible to all other drugs, except cotrimoxazole (47% susceptibility). Of the 52 Moraxella catarrhalis
isolates, 98% produced b-lactamase, and the MIC of all drugs was 4 mg/L, with the exception of ampicillin,
where the MIC90 was 8 mg/L.
Conclusions When these data are compared with previous reports, our findings suggest that the prevalence
of pneumococci that are resistant to agents such as penicillin and cotrimoxazole may be increasing in Brazil,
which highlights the need to continue surveillance programs.
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INTRODUCTION
Antibiotic resistance in the common respiratory pathogens
Streptococcus pneumoniae, Haemophilus influenzae and Moraxella
catarrhalis is increasing world-wide. As a consequence, acute
respiratory infections represent a major public health challenge
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for both clinicians and the pharmaceutical industry. Although
a variety of antimicrobial agents are available to treat these
infections, widespread use in many different countries may
be the reason that many bacteria have become partially or
completely resistant to some of these agents [1].
Penicillin-resistant pneumococci are of particular concern
[2]. In 1996–97, the prevalence of penicillin-intermediate
strains (minimum inhibitory concentration (MIC) of 0.12–
1.0 mg/L) in the United States was 20% and the prevalence
of highly resistant strains (MIC  2 mg/L) was 14% [3]. The
correlation between penicillin resistance and resistance to other
b-lactams, macrolides and the agent cotrimoxazole [3–5] heigh-
tens the public health risk posed by penicillin-resistant S. pneu-
moniae. Therefore, careful selection of antibiotics with low
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resistance potential and excellent antimicrobial activity against
highly resistant pneumococci is currently one of the best stra-
tegies to delay or decrease the emergence of highly resistant
strains of S. pneumoniae [1].
The prevalence of b-lactamase-producing strains of H.
influenzae is also reported to be increasing [2]. In 1995, the
prevalence of b-lactamase-producing H. influenzae isolates was
15.4% in Europe and 28.4% in the USA [6]. During the 1996–
97 respiratory season in the USA, the prevalence of b-lac-
tamase-producing H. influenzae strains was 33.4% [4], and in
1996, the prevalence in France, Belgium and Spain was greater
than 20% [7].
During the 1990s, the prevalence of b-lactamase-producing
strains of M. catarrhalis rose to more than 90% in Europe and
the USA [4,6–8]. In Europe, the present level of b-lactamase
production marks a sharp increase from the 1992–93 prevalence
of 70% [6].
In Brazil, several antimicrobial resistance surveillance studies
were conducted in the early and mid-1990s [9–13], but the most
recently published report concerned clinical isolates collected in
1996 [7]. In 1997–98, we collected respiratory pathogens from
five different centers in Brazil and performed susceptibility
testing for 10 antimicrobial agents in a central laboratory.
MATERIALS AND METHODS
Bacterial isolates
During 1997–98, 359 S. pneumoniae, 219 H. influenzae and 52
M catarrhalis isolates were collected from five different Brazilian
hospitals. All isolates were shipped to the MRL laboratory,
where S. pneumoniae and M. catarrhalis isolates were subcultured
on sheep blood agar plates and H. influenzae isolates were
subcultured on chocolate agar.
The percentage breakdown of specimen source for each
organism was as follows:
S. pneumoniae; 46% respiratory, 27% blood and 27% other,
H. influenzae; 83% respiratory, 8% blood and 9% other
M. catarrhalis; 100% respiratory isolates.
Antimicrobial susceptibility testing
The isolates were tested for MICs of amoxycillin/clavulanate,
ceftriaxone, cefuroxime, azithromycin, clarithromycin, levo-
floxacin and cotrimoxazole. In addition, S. pneumoniae was
tested against penicillin and vancomycin, and H. influenzae and
M. catarrhalis were tested against ampicillin.
For S. pneumoniae and H. influenzae, antibiotic susceptibility
testing was conducted by broth microdilution according to
the recommendations of the National Committee for Clinical
Laboratory Standards (NCCLS) [14]. No NCCLS standards
exist for M. catarrhalis. A McFarland 0.5 suspension (approxi-
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mately 1  108 colony-forming units (CFU)/mL) of each
organism was prepared from an overnight agar culture, and this
suspension was used to inoculate the broth microdilution plates
to obtain a final inoculum of approximately 5  105 CFU/mL.
Cation-adjusted Mueller–Hinton broth supplemented with 2–
5% lysed horse blood was used for S. pneumoniae, cation-
adjusted Mueller–Hinton Broth was used for M. catarrhalis, and
Haemophilus test medium was used for H. influenzae. The
inoculated plates were incubated at 35 °C for 20–24 h in ambi-
ent air prior to determining MICs. Streptococcus pneumoniae
ATCC 49619 and H. influenzae ATCC 49247 were used as
controls.
Analysis of results
Specimen source and age group data were compared using the
x2-square test (EpiInfo version 6, Centers for Disease Control
and Prevention, Atlanta, GA, USA). A P-value of 0.05 was
considered significant.
RESULTS
Since penicillin was chosen as the surrogate marker for moni-
toring antibiotic resistance in S. pneumoniae, all of the 1997–98
isolates were tested for their susceptibility to penicillin. The
results in Table 1 show that 77.2% (277 isolates) of the Brazilian
strains were susceptible to penicillin (MIC  0.06 mg/L),
18.7% (67 isolates) were intermediate (0.12–1.0 mg/L) and
4.2% (17 isolates) were resistant (MIC  2 mg/L). The impact
of penicillin resistance on susceptibility to other antimicrobials
was also analyzed. Approximately 96% of all isolates were sus-
ceptible to amoxycillin/clavulanate. All (100%) of the isolates
that were susceptible or intermediate to penicillin were also
susceptible to amoxycillin/clavulanate (minimum inhibitory
concentrations for 90% effectiveness (MIC90s) of 0.03 mg/L
and 0.12 mg/L, respectively). However, only 6.7% of the 15
penicillin-resistant isolates were susceptible to amoxy-
cillin/clavulanate. A similar relationship also was seen for the
cephalosporins, ceftriaxone and cefuroxime, where all peni-
cillin-susceptible isolates were susceptible to these two agents.
Approximately 99% of the 67 penicillin-intermediate strains
and 6.7% of the penicillin-resistant strains were susceptible
to ceftriaxone. As with amoxycillin/clavulanate, there was an
incremental increase in the MIC90 of ceftriaxone for all isolates
as the penicillin status shifted from susceptible to resistant. The
most dramatic shift in susceptibility was seen with cefuroxime
where all of the penicillin-resistant strains were also resistant to
cefuroxime.
For both azithromycin and clarithromycin, the prevalences
of susceptible isolates by penicillin interpretative category were
identical, and for both agents, the resistance levels increased
with increasing penicillin resistance (13% of the penicillin-
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Table 1 Activity of nine antimicrobial agents against 359 Brazilian isolates of Streptococcus pneumoniae
MIC (mg/L)
Antibiotic/phenotype n Range MIC50 MIC90 %S %I %R
Penicillin
All 359 0.03–4 0.03 0.25 77.2 18.7 4.2
Penicillin-susceptible 277 0.03–0.06 0.03 0.06 100 0 0
Penicillin-intermediate 67 0.12–1 0.25 0.5 0 100 0
Penicillin-resistant 15 2–4 2 4 0 0 100
Amoxicillin/clavulanate
All 359 0.015–4 0.03 0.06 96.1 2.2 1.7
Penicillin-susceptible 277 0.015–0.25 0.03 0.03 100 0 0
Penicillin-intermediate 67 0.015–0.25 0.06 0.12 100 0 0
Penicillin-resistant 15 0.5–4 1 2 6.7 53.3 40
Ceftriaxone
All 359 0.015–2 0.03 0.12 95.8 2.8 1.4
Penicillin-susceptible 277 0.015–0.5 0.03 0.06 100 0 0
Penicillin-intermediate 67 0.03–2 0.12 0.25 98.5 0 1.5
Penicillin-resistant 15 0.5–2 1 2 6.7 66.7 26.7
Cefuroxime
All 359 0.12–8 0.12 0.5 92.5 2.2 5.3
Penicillin-susceptible 277 0.12–0.5 0.12 0.25 100 0 0
Penicillin-intermediate 67 0.12–8 0.25 1 82.1 11.9 6
Penicillin-resistant 15 2–8 8 8 0 0 100
Azithromycin
All 359 0.03–4 0.03 0.06 95.3 0.6 4.2
Penicillin-susceptible 277 0.03–4 0.03 0.06 97.5 0.4 2.2
Penicillin-intermediate 67 0.03–4 0.03 4 88.1 1.5 10.4
Penicillin-resistant 15 0.03–4 0.03 4 86.7 0 13.3
Clarithromycin
All 359 0.015–32 0.015 0.03 95.3 0 4.7
Penicillin-susceptible 277 0.015–32 0.015 0.03 97.5 0 2.5
Penicillin-intermediate 67 0.015–32 0.03 8 88.1 0 11.9
Penicillin-resistant 15 0.015–32 0.015 32 86.7 0 13.3
Levofloxacin
All 359 0.12–8 0.5 1 99.7 0 0.3
Penicillin-susceptible 277 0.12–8 0.5 1 99.6 0 0.4
Penicillin-intermediate 67 0.5–1 0.5 1 100 0 0
Penicillin-resistant 15 0.25–1 0.5 1 100 0 0
Cotrimoxazole
All 359 0.03–4 1 4 48.2 28.4 23.4
Penicillin-susceptible 277 0.03–4 0.5 4 57.8 23.8 18.4
Penicillin-intermediate 67 0.12–4 2 4 19.4 46.3 34.3
Penicillin-resistant 15 2–4 4 4 33.3 66.7
Vancomycin
All 359 0.06–1 0.25 0.5 100 0 0
Penicillin-susceptible 277 0.06–1 0.25 0.5 100 0 0
Penicillin-intermediate 67 0.12–1 0.5 0.5 100 0 0
Penicillin-resistant 15 0.25–0.5 0.5 0.5 100 0 0
MIC, minimum inhibitory concentration; MIC50, 50% MIC; MIC90, 90% MIC; %S, % susceptible; %I, % intermediate; %R, % resistant.
resistant strains were macrolide resistant). The effect of peni-
cillin resistance was even more pronounced when MIC90s were
examined, i.e. the MIC90 of clarithromycin for the penicillin-
susceptible strains was 0.03 mg/L and for penicillin-resistant
strains was greater than 32 mg/L. Only 48% of the strains were
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susceptible to cotrimoxazole, and none of the penicillin-resist-
ant strains were susceptible to cotrimoxazole.
The only antimicrobial agents that appeared unaffected by
penicillin status were levofloxacin and vancomycin. All the
pneumococcal isolates were susceptible to vancomycin and only
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one isolate was resistant to levofloxacin. The levofloxacin-
resistant isolate was susceptible to penicillin (MIC  0.03
mg/L), suggesting that resistance was unrelated to the penicillin
susceptibility status of the isolate. In fact, this isolate was sus-
ceptible to all agents under study other than levofloxacin.
The levofloxacin, azithromycin, clarithromycin and cotri-
moxazole MIC distributions for pneumococci are shown in
Table 2. The MIC90 was below the NCCLS interpretative
breakpoint for levofloxacin (MIC90 = 1 mg/L), azithromycin
(MIC90 = 0.06 mg/L) and clarithromycin (MIC90  0.03 mg/
L), but not for cotrimoxazole (MIC90 = 4 mg/L).
For H. influenzae and M. catarrhalis, b-lactamase production
was used as the primary resistance marker. Of the 219 isolates
of H. influenzae, 24 (11%) produced b-lactamase. The results
in Table 3 show the susceptibility of H. influenzae to eight
different antimicrobial agents. All isolates were susceptible to
amoxycillin/clavulanate regardless of their b-lactamase status,
but with ampicillin, 89% of the isolates were susceptible. No
b-lactamase-producing strain was susceptible to ampicillin. The
cephalosporins and macrolides appeared unaffected by the pro-
duction of b-lactamase. All isolates were susceptible to ceftri-
axone, cefuroxime and azithromycin and 92% were susceptible
to clarithromycin. Only 47% of isolates were susceptible to
cotrimoxazole, but the b-lactamase-producing strains were
nearly twice as often resistant (79%) as the b-lactamase-negative
organisms (41% resistance). The presence of b-lactamase had
no effect on the levofloxacin susceptibility or MIC90 for H.
influenzae (MIC90 = 0.015 mg/L).
Of the 52 isolates of M. catarrhalis that were collected during
this study, 51 produced b-lactamase (Table 4). The MIC90 of
ampicillin for the b-lactamase-positive isolates was greater than
8 mg/L, but MICs as low as 0.12 mg/L were detected. In
contrast to H. influenzae, all the b-lactamase-producing organ-
isms had low cotrimoxazole MICs (range: 0.06–2 mg/L).
Specimen source and patient age data were collected on each
isolate, making it possible to analyze the potential association
of these parameters with antimicrobial susceptibility. The strati-
fication of susceptibility data for S. pneumoniae by specimen
source (blood, respiratory, or other specimen sources) did not
Table 2 Minimum inhibitory concentration (MIC) distributions of levofloxacin, azithromycin, clarithromycin and cotrimoxazole
against 359 isolates of Streptococcus pneumoniae
No. of strains (% strains) at this MIC (mg/L)
Antibiotic 0.03 0.06 0.12 0.25 0.5 1 2 4 8
Levofloxacin 1 (0.3) 7 (2.2) 215 (62.1) 131 (98.6)a 4 (99.7) 0 (99.7) 1 (100)
Azithromycin 298 (83.0) 40 (94.2)a 3 (95.0) 1 (95.3) 0 (95.3) 2 (95.8) 2 (96.4) 7 (98.3) 6 (100)
Clarithromycin 341 (95.0)a 0 (99.0) 0 (95.0) 1 (95.3) 0 (95.3) 2 (95.8) 2 (96.4) 1 (96.6) 12 (100)
Cotrimoxazole 3 (0.8) 34 (10.3) 82 (33.2) 25 (40.4) 29 (48.2) 19 (53.5) 83 (76.6) 72 (96.7)a 12 (100)
a Italics represents minimum inhibitory concentration for 90% effectiveness.
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result in a significant impact on the prevalence of susceptible
strains to any of the antimicrobial agents tested (P  0.5 by
x2-square test). Similarly, when the data were stratified accord-
ing to age group (patients 12 years and 12 years), no
significant difference was seen between age groups for any of
the antimicrobial agents under study (P  0.1 by x2-square
test). However, we noted that all 17 of the penicillin-resistant
pneumococci were isolated from patients 12 years of age.
DISCUSSION
Routine surveillance of antimicrobial resistance and restriction
of the inappropriate use of antibiotics are strategies often cited
as being critical for the successful management of infectious
diseases. Since geographical borders no longer confine infec-
tious diseases, surveillance studies are now being conducted
nationally and internationally. In particular, respiratory infec-
tions have attracted considerable attention because of their high
incidence, morbidity burden and economic impact. This study
was designed to determine the current status of resistance in
respiratory pathogens in Brazil during 1997–98. A number of
studies have been conducted in Brazil during the last decade
[7,9–13,15], but most of them included only S. pneumoniae
isolates. Furthermore, since antimicrobial resistance patterns
can change from one year to the next, it is important to examine
how the current prevalences may have changed from those of
previous years.
The prevalence of penicillin-nonsusceptible isolates of S.
pneumoniae appears to be increasing in Brazil. In a 1988–92
study of 345 pneumococci, Sessegolo et al. determined that
the prevalence of penicillin-nonsusceptible strains was 18.7%
(17.9% intermediate and 0.8% resistant) [9]. Brandileone et al.
investigated the susceptibility of 1252 pneumococcal isolates
collected from different regions of Brazil and found the preva-
lence of penicillin-nonsusceptible isolates had increased from
9.6% in 1993 to 20.6% in 1996, for an overall prevalence of
15.1% (14.5% intermediate and 0.6% resistant) [11]. Another
study involving 1996 isolates determined that 17.9% of pneu-
mococci were penicillin intermediate and 2.1% were resistant
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Table 3 Activity of nine antimicrobial agents against 219 Brazilian isolates of Haemophilus influenzae
MIC (mg/L)
n Range MIC50 MIC90 %S %I %R
Amoxicillin/clavulanate
All 219 0.015–4 0.5 1 100 0 0
b-lactamase positive 24 0.5–4 1 4 100 0 0
b-lactamase negative 195 0.015–4 0.5 1 100 0 0
Ampicillin
All 219 0.12–8 0.25 2 89 1.4 9.6
b-lactamase positive 24 2–8 8 8 0 12.5 87.5
b-lactamase negative 195 0.12–1 0.25 0.5 100 0 0
Ceftriaxone
All 219 0.015–1 0.015 0.03 100 0 0
b-lactamase positive 24 0.015–0.25 0.015 0.06 100 0 0
b-lactamase negative 195 0.015–1 0.015 0.03 100 0 0
Cefuroxime
All 219 0.12–4 1 2 100 0 0
b-lactamase positive 24 0.25–4 1 2 100 0 0
b-lactamase negative 195 0.12–4 1 2 100 0 0
Azithromycin
All 219 0.03–4 1 2 100 0 0
b-lactamase positive 24 0.12–2 0.5 1 100 0 0
b-lactamase negative 195 0.03–4 1 2 100 0 0
Clarithromycin
All 219 0.015–16 8 8 92.2 7.8 0
b-lactamase positive 24 0.25–16 4 8 91.7 8.3 0
b-lactamase negative 195 0.015–16 8 8 92.3 7.7 0
Levofloxacin
All 219 0.004–0.5 0.015 0.015 100 0 0
b-lactamase positive 24 0.008–0.5 0.015 0.015 100 0 0
b-lactamase negative 195 0.004–0.5 0.015 0.015 100 0 0
Cotrimoxazole
All 219 0.015–4 1 4 47 7.8 45.2
b-lactamase positive 24 0.06–4 4 4 16.7 4.2 79.2
b-lactamase negative 195 0.015–4 0.5 4 50.8 8.2 41
[7]. Our findings suggest that the prevalence continues to
increase since 22.9% of the isolates collected in 1997–98 were
not susceptible to penicillin (18.7% intermediate and 4.2%
resistant).
In 1996, Levin et al. reported that 31 of 50 Brazilian S.
pneumoniae isolates were resistant to at least one of the drugs
under study [10], but very few studies of Brazilian isolates have
reported antimicrobial resistance profiles for agents other than
penicillin. Among Brazilian pneumococci isolated from 1988
to 1992 [9], macrolide susceptibility was 94% and in 1996
the prevalence was 95% [7], findings that our 1997–98 study
corroborates (95%), but cotrimoxazole susceptibility was
reported to be 71% in 1988–92 [9] and 64.2% in 1996 [7],
which suggests the prevalence of susceptible isolates declined
to 48% in 1997–98.
In common with other studies of Brazilian isolates, we found
that the penicillin susceptibility category of pneumococcal iso-
lates had an impact on resistance to other drug classes. Sessegolo
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et al. [9], who studied resistance in 288 isolates of S. pneumoniae
collected between 1988 and 1992, determined that the two
isolates that were resistant to penicillin also had reduced sus-
ceptibilities to cephalosporins and the macrolide erythromycin.
In addition, the 47 isolates that were intermediate for penicillin
also had reduced susceptibilities to other antibiotic classes. Simi-
larly, Brandileone et al. [11] reported that penicillin-resistant
isolates tended to be resistant to erythromycin, clindamycin,
tetracycline, and cotrimoxazole. In our study, the prevalence
of antimicrobial resistance increased with penicillin resistance
for amoxycillin-clavulanate, ceftriaxone, cefuroxime, azi-
thromycin, clarithromycin, and cotrimoxazole.
In 1993, Brandileone et al. [15] collected 360 strains of pneu-
mococci from Brazilian children with invasive infections. The
prevalence of penicillin-nonsusceptible strains was similar to
those reported in other studies (1.4% resistant and 20% inter-
mediate) but were more common among children under 2
years of age than children aged 3–5 years (P  0.05). In contrast
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Table 4 Activity of nine
antimicrobial agents against
52 Brazilian isolates of Moraxella
catarrhalis
MICs (mg/ml)
n Range MIC50 MIC90
Amoxicillin/clavulanate
All 52 0.015–0.5 0.06 0.25
b-lactamase positive 51 0.015–0.5 0.06 0.25
b-lactamase negative 1 0.015–0.015 0.015 0.015
Ampicillin
All 52 0.12–8 2 8
b-lactamase positive 51 0.12–8 2 8
b-lactamase negative 1 0.12–0.12 0.12 0.12
Ceftriaxone
All 52 0.015–1 0.06 0.5
b-lactamase positive 51 0.015–1 0.06 0.5
b-lactamase negative 1 0.03–0.03 0.03 0.5
Cefuroxime
All 52 0.25–4 1 2
b-lactamase positive 51 0.25–4 1 2
b-lactamase negative 1 0.5–0.5 0.5 0.5
Azithromycin
All 52 0.03–0.06 0.03 0.03
b-lactamase positive 51 0.03–0.06 0.03 0.03
b-lactamase negative 1 0.03–0.03 0.03 0.03
Clarithromycin
All 52 0.015–0.25 0.06 0.12
b-lactamase positive 51 0.015–0.25 0.06 0.12
b-lactamase negative 1 0.12–0.12 0.12 0.12
Levofloxacin
All 52 0.03–1 0.03 0.06
b-lactamase positive 51 0.03–1 0.03 0.06
b-lactamase negative 1 0.06–0.06 0.06 0.06
Cotrimoxazole
All 52 0.06–4 0.25 0.5
b-lactamase positive 51 0.06–2 0.25 0.5
b-lactamase negative 1 4–4 4 4
with this earlier study, we did not detect a significant difference
between patient age groups in the prevalence of penicillin-
resistant pneumococci. The criteria for our age groups (patients
12 years and patients 12 years) did not allow us to dif-
ferentiate between the two groupings of pediatric patients ana-
lyzed by Brandileone et al., perhaps accounting for the disparate
findings.
Penicillin-resistant lineages of pneumococci seem to be
increasing independently through horizontal spread of resist-
ance genes [11]. As a result, clusters of penicillin resistance have
emerged over distant regions in Brazil. In 1993–96, the Pan
American Health Organization sponsored a study of Latin
American countries (Brazil, Argentina, Chile, Colombia, Mex-
ico and Uruguay) to characterize invasive isolates of S. pneu-
moniae from patients under 6 years of age with clinical symptoms
of pneumonia, leading to the discovery that two internationally
spread clones comprised more than 80% of the strains with
penicillin MICs 1 mg/L [13].
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With regard to the other respiratory pathogens, H. influenzae
and M. catarrhalis, nearly all the antimicrobial agents under
study were highly active. The exceptions were ampicillin and
cotrimoxazole. For H. influenzae, b-lactamase production
among 1997–98 Brazilian isolates (10%) was lower than
observed in 1996–97 US isolates (33%) [3], but the reverse was
true for b-lactamase production among M. catarrhalis, which
was 98% among Brazilian isolates but 93% in the 1996–97 US
study [3].
In light of the resistance patterns that have emerged in recent
years, S. pneumoniae is perhaps the most significant respiratory
pathogen. Considerable alarm has arisen at the recent increase
in resistance among pneumococci to b-lactams and macrolides.
What is proving to be of particular interest is the fact that
quinolones such as levofloxacin seem to retain activity against
S. pneumoniae and do not yet show cross-resistance to other
antimicrobial classes. In the United States fluoroquinolone
resistance in S. pneumoniae is still relatively rare regardless of
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susceptibility to penicillin [3,4,16,17], as was true in our study
of Brazilian isolates.
Although quinolones remain highly active against S. pneu-
moniae, there is no room for complacency. Mutants of S. pne-
umoniae that are resistant to quinolones have been generated
in the laboratory. The primary targets for quinolones in S.
pneumoniae are DNA gyrase (gyrA and gyrB) and topoisomerase
IV (parC and parE), and mutations contributing to reduced
susceptibility to ciprofloxacin have been mapped to specific
resistance hotspots in these genes [18]. In a separate study,
Fukuda and Hiramatsu [19] were able to select parC mutants in a
wild-type strain of S. pneumoniae in the presence of levofloxacin,
suggesting that this is the primary target for the drug in this
organism. Furthermore, quinolone-resistant clinical isolates
from patients in North America, France and Belgium were
shown by Jorgensen et al. [20] to have mutations in gyrA,
parC and parE, which contributed to resistance to the newer
fluoroquinolones. In addition to modified target site, evidence
suggests that a multidrug efflux mechanism (pmrA) may also
contribute to fluoroquinolone resistance in pneumococci [21].
Interestingly, in a study with an efflux pump mutant of S.
pneumoniae, the activity of levofloxacin was unaffected, in con-
trast to the reduced activity of some of the other newer qui-
nolones such as moxifloxacin and trovafloxacin [22]. Since
fluoroquinolone resistance mechanisms have been detected in
S. pneumoniae, clearly a need exists to continuously monitor the
status of the activity of this class of agents against target organ-
isms so that appropriate actions may be taken, should resistance
emerge.
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